Home » Stocks » VNDA

Vanda Pharmaceuticals Inc. (VNDA)

Stock Price: $17.83 USD -0.03 (-0.17%)
Updated May 11, 2021 4:00 PM EDT - Market closed
Market Cap 997.66M
Revenue (ttm) 252.84M
Net Income (ttm) 31.50M
Shares Out 55.15M
EPS (ttm) 0.56
PE Ratio 31.90
Forward PE 30.30
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $17.83
Previous Close $17.86
Change ($) -0.03
Change (%) -0.17%
Day's Open 17.53
Day's Range 17.38 - 18.10
Day's Volume 249,522
52-Week Range 9.00 - 20.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

WASHINGTON, May 5, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2021. "Despite seasonal ...

6 days ago - PRNewsWire

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

WASHINGTON, April 20, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021, after the marke...

3 weeks ago - PRNewsWire

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA)

1 month ago - Business Wire

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending secu...

2 months ago - Business Wire

The IBD SmartSelect Composite Rating for Vanda Pharmaceuticals increased from 78 to 97 Friday. The post Vanda Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on I...

2 months ago - Investors Business Daily

WASHINGTON, Feb. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2020...

3 months ago - PRNewsWire

WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, 20...

3 months ago - PRNewsWire

The biotech's sleep drug Hetlioz gained an expanded approval.

5 months ago - The Motley Fool

News of an update from the U.S. Food and Drug Administration (FDA) pushed Vanda Pharmaceuticals Inc.

5 months ago - 24/7 Wall Street

WASHINGTON, Dec. 1, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule an...

5 months ago - PRNewsWire

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, SRGA, PETS, SRDX
6 months ago - GuruFocus

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...

Other stocks mentioned: CPRX, PRDO, SBR, XBIT
6 months ago - GuruFocus

WASHINGTON, Oct. 28, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020. "Vanda conti...

6 months ago - PRNewsWire

WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IN...

6 months ago - PRNewsWire

WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020, after the m...

6 months ago - PRNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, TECH, XBIT
7 months ago - Investopedia

WASHINGTON, Aug. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

8 months ago - PRNewsWire

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) took another big step forward in the fight against COVID-19 on Tuesday morning.

8 months ago - 24/7 Wall Street

WASHINGTON, Aug. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

8 months ago - PRNewsWire

Vanda Pharmaceuticals Is Still Undervalued Despite Strong Performance During The Pandemic

8 months ago - Seeking Alpha

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

9 months ago - PRNewsWire

WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the ma...

9 months ago - PRNewsWire

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDA...

9 months ago - Business Wire

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

9 months ago - Zacks Investment Research

WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individ...

9 months ago - PRNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, TRIL, VRTX, XBIT
11 months ago - Investopedia

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

11 months ago - Benzinga

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Cl...

11 months ago - PRNewsWire

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals...

11 months ago - PRNewsWire

No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.

11 months ago - The Motley Fool

Third-quarter results from a COVID-19 trial could send this stock soaring.

11 months ago - The Motley Fool

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Vanda Pharmaceuticals: Undervalued Despite Its COVID-19 Treatment Potential

1 year ago - Seeking Alpha

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

1 year ago - Zacks Investment Research

Vanda Pharmaceutical CEO on coronavirus vaccine

YouTube video

Dr. Mihael Polymeropoulos, Vanda Pharmaceuticals CEO, joins "Closing Bell" to discuss the latest updates on the coronavirus.

1 year ago - CNBC Television

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

Other stocks mentioned: FHN, JHG, PCG, PFG, TCRD
1 year ago - Zacks Investment Research

Vanda Loses Against The FDA, And Other News: The Good, Bad, And Ugly Of Biopharma

1 year ago - Seeking Alpha

On the tailwind of a growing U.S. economy, in which gross domestic product is projected to have hit a 2% annualized gain in the final quarter of 2019, the Russell 2000 Index rose 25.8% to $1,657.64 per ...

Other stocks mentioned: FORM, IRBT
1 year ago - GuruFocus

Vanda: Significantly Underappreciated

1 year ago - Seeking Alpha

These five stocks should benefit from the “January bounce” that often buoys up the previous year’s losers.

Other stocks mentioned: CNX, CPS, CXO, GDOT
1 year ago - Forbes

Energy stocks, and to a lesser extent bank stocks, have been the market’s whipping boys in 2019.

Other stocks mentioned: CNX, CPS, CXO, GDOT
1 year ago - GuruFocus

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment... [Read more...]

Industry
Biotechnology
IPO Date
Apr 12, 2006
CEO
Mihael Polymeropoulos
Employees
292
Stock Exchange
NASDAQ
Ticker Symbol
VNDA
Full Company Profile

Financial Performance

In 2020, VNDA's revenue was $248.17 million, an increase of 9.23% compared to the previous year's $227.19 million. Earnings were $23.34 million, a decrease of -79.80%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for VNDA stock is "Buy." The 12-month stock price forecast is 24.00, which is an increase of 34.60% from the latest price.

Price Target
$24.00
(34.60% upside)
Analyst Consensus: Buy